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microtubule disruption, and inhibited anterograde and retro-
grade trafficking. In brain sections from AD patients and the 
5XFAD transgenic mouse model of amyloid pathology, dys-
trophic neurite halos with BACE1 elevation around amyloid 
plaques exhibited aberrant tubulin accumulations or voids. 
At the ultrastructural level, peri-plaque dystrophies were 
strikingly devoid of microtubules and replete with multi-
lamellar vesicles resembling autophagic intermediates. Pro-
teins of the microtubule motors, kinesin and dynein, and 
other neuronal proteins were aberrantly localized in peri-
plaque dystrophies. Inactive pro-cathepsin D also accumu-
lated in peri-plaque dystrophies, indicating reduced lyso-
somal function. Most importantly, BACE1 accumulation in 
peri-plaque dystrophies caused increased BACE1 cleavage 
of APP and Aβ generation. Our study supports the hypoth-
esis that Aβ induces microtubule disruption in presynaptic 
dystrophic neurites that surround plaques, thus impairing 
axonal transport and leading to accumulation of BACE1 and 
exacerbation of amyloid pathology in AD.
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Introduction
The β-amyloid (Aβ) peptide, the major component of 
amyloid plaques, has a crucial early role in Alzheimer’s 
disease (AD) pathogenesis [58]. The membrane aspartic 
protease β-site amyloid precursor protein (APP) cleav-
ing enzyme 1 (BACE1) is the major β-secretase enzyme 
that initiates the production of Aβ from APP [20, 54, 66, 
79]. Mutations in APP at the BACE1 cleavage site cause 
(K670N/M671L [38], A673V [8]) or prevent (A673T 
Abstract Alzheimer’s disease (AD) is characterized by 
amyloid plaques composed of the β-amyloid (Aβ) peptide 
surrounded by swollen presynaptic dystrophic neurites con-
sisting of dysfunctional axons and terminals that accumu-
late the β-site amyloid precursor protein (APP) cleaving 
enzyme (BACE1) required for Aβ generation. The cellular 
and molecular mechanisms that govern presynaptic dys-
trophic neurite formation are unclear, and elucidating these 
processes may lead to novel AD therapeutic strategies. Pre-
vious studies suggest Aβ may disrupt microtubules, which 
we hypothesize have a critical role in the development of 
presynaptic dystrophies. To investigate this further, here 
we have assessed the effects of Aβ, particularly neurotoxic 
Aβ42, on microtubules during the formation of presynaptic 
dystrophic neurites in vitro and in vivo. Live-cell imaging 
of primary neurons revealed that exposure to Aβ42 oligom-
ers caused varicose and beaded neurites with extensive 
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[24]) AD by increasing or decreasing BACE1 cleavage of 
APP and Aβ production, respectively. Also, a mutation at 
the β′-site (E682K [87]) causes AD by shifting BACE1 
cleavage toward β-site processing of APP and Aβ genera-
tion. These mutations and other evidence strongly sup-
port therapeutic BACE1 inhibition for AD [67]. BACE1 
inhibitor drugs are in clinical trials; however, the safety 
and efficacy of these drugs are unknown. BACE1 null 
mice have multiple neurological phenotypes indicating 
BACE1 inhibitor drugs could have mechanism-based tox-
icities [67]. BACE1 levels are elevated in AD brain [14, 
18, 31, 80, 86] potentially necessitating high doses of 
BACE1 inhibitor drugs, thus increasing the risk of side 
effects. Lowering/normalizing BACE1 levels in AD brain 
rather than direct inhibition of enzyme activity offers 
an alternative therapeutic approach that could avoid 
BACE1 inhibitor side effects. Elucidating the mechanism 
of BACE1 elevation in AD is essential for developing 
BACE1 lowering strategies.
While the mechanism of BACE1 elevation in brains 
of AD patients or mouse models of AD is not yet clear, 
recent data indicate that BACE1 levels are upregulated 
during stresses associated with AD risk, such as energy 
deprivation [39, 68], hypoxia and stroke [56, 71, 84], oxi-
dative stress [61], and traumatic brain injury [2, 65]. A 
large number of molecular pathways have been proposed 
to increase BACE1 levels: increased caspase 3 activity 
leading to impaired lysosomal degradation [26, 60], Cdk5 
phosphorylation of transcription factor Stat3 [72], altered 
microRNAs [3, 12, 17, 69, 88], transcription factor HIF1α 
activity, [84], elevated phosphorylation of the elongation 
initiation factor eIF2α [39]. Thus, BACE1 appears to be 
a stress-response protein that can be regulated via diverse 
molecular pathways, making it challenging to identify the 
precise mechanism(s) involved in AD-relevant BACE1 
elevation.
Insights into the mechanism of BACE1 elevation in 
AD have come from analysis of the localization pattern of 
increased BACE1 in the brains of AD patients and trans-
genic mouse models of amyloid pathology. Importantly, 
BACE1 elevation is not uniform throughout the brain, but 
is concentrated in presynaptic dystrophic neurites that sur-
round amyloid plaques [25, 86] where it potentially spurs 
Aβ generation and plaque growth. Close proximity to 
plaques is associated with presynaptic dystrophy and Aβ42 
oligomers increase BACE1 levels in cultured neurons [48, 
49], thus implicating Aβ neurotoxicity in these processes. 
Reticulon 3 is involved in dystrophic neurite formation 
[19, 52, 53], but the role of Aβ is poorly understood. We 
recently determined that BACE1-YFP expressed from a 
doxycycline-inducible transgene lacking the endogenous 
5′ UTR that controls BACE1 translation accumulates 
around plaques in an APP transgenic mouse similar to that 
observed in AD [48]. These results suggest that BACE1 
elevation in AD occurs via a post-translational mechanism 
involving Aβ neurotoxicity that is closely associated with 
amyloid plaques, and does not appear to involve transcrip-
tional or translational regulation.
Here, we show by live-cell imaging that Aβ42 oligom-
ers cause microtubule disruption and neuritic beading. In 
BACE1-positive dystrophic neurites surrounding amyloid 
plaques of AD and the 5XFAD transgenic mouse model, 
tubulin isoforms are mis-localized, often forming aberrant 
accumulations or voids. By EM, 5XFAD dystrophic axons 
appear distended with multi-lamellar vesicles, but notably 
lack intact microtubules. This observation, together with 
aberrant localization of microtubule motor proteins and 
other neuronal proteins, and evidence of reduced lysoso-
mal function and autophagic intermediate accumulation, 
suggests that microtubule-based transport is impaired in 
dystrophic neurites surrounding amyloid plaques. Most 
importantly, BACE1 and APP accumulate in peri-plaque 
dystrophies to very high levels and lead to increased gener-
ation of BACE1-cleaved APP products, including Aβ42 that 
may exacerbate plaque growth. Taken together, our results 
suggest that amyloid plaques cause a local toxic effect, pos-
sibly mediated by soluble Aβ42 oligomers, that generates 
presynaptic dystrophic neurites by disrupting microtubles 
and impairing transport. As a result, peri-plaque dystro-
phies accumulate BACE1, APP, and γ-secretase, further 
contributing to Aβ generation and plaque growth in a feed-
forward mechanism.
Materials and methods
Primary neuron culture, Aβ42 oligomer preparation, 
and immunofluorescence
E15.5-16.5 C57BL/6 mouse cortical neurons were plated 
on poly-l-lysine (Sigma) coverslips in 12-well plates 
(150,000 cells/well) in neurobasal media supplemented 
with 2 % B-27, 500 μM glutamine, 10 % horse serum, and 
2.5 μM glutamate. After 2 h, medium was changed to neu-
robasal with 2 % B-27, 500 μM glutamine, and 2.5 μM 
glutamate. After 1–3 days, medium was replaced with neu-
robasal plus 2 % B-27 and 500 μM glutamine. Following 
9 days in culture, neurons were treated with 1 μM Aβ42 
oligomers or vehicle prepared as previously described [48, 
55]. Briefly, lyophilized recombinant Aβ42 peptide (rPep-
tide, cat# A-1163-1) was HFIP treated, dried down, then 
resuspended to 5 mM in dry DMSO (Molecular Probes, # 
D12345) and brought to 100 μM in cold, 4 mM HEPES 
pH 8, incubated on ice at 4 °C for 24 h to generate oli-
gomers. For control cultures, DMSO alone was added to 
4 mM HEPES pH 8 and incubated as described. After 72 h 
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of Aβ42 treatment, neurons were fixed for 20 min in 4 % 
paraformaldehyde, 0.12 M sucrose in PBS, permeabilized 
in 0.5 % Triton, and incubated in anti-βIII tubulin mouse 
monoclonal antibody (TuJ1, gift of Dr. Lester Binder, 
1:500) followed by donkey anti-mouse Alexa 568-con-
jugated secondary antibody (Molecular Probes, 1:1000) 
and counterstained with 300 nM DAPI. Coverslips were 
mounted using Prolong Gold (Molecular Probes), and 
images acquired on a Nikon A1 confocal microscope with a 
60× objective (NA 1.4) and NIS Elements software.
Live imaging of neurons
Primary neurons prepared as above were plated (150,000 
cells/dish) in 35-mm glass-bottom culture dishes (Mat-
Tek # P35G-1.5-14C). After 11–12 days, medium was 
replaced with neurobasal containing 250 nM of Tubulin 
Tracker (Molecular Probes #T34075), neurons incubated 
for 30 min at 37 °C, rinsed twice with warmed media, and 
original media replaced. 10 μM Aβ42 oligomers or vehi-
cle, prepared as above, were added and neurons imaged on 
an Andor Spinning Disk confocal microscope with a 60× 
objective (NA 1.49). Imaging began within 30 min of treat-
ment and continued for 3 h, with a 100-ms exposure taken 
every 5 min, or 6 h, with a 100-ms exposure taken every 
hour, at 20–25 locations on the coverslip. Images were cap-
tured using Metamorph and intensity quantified in ImageJ. 
Statistical analysis was done using a two-tailed t test in 
Prism.
Mice
5XFAD mice were generated as previously described [40] 
and maintained by crossing transgene positive males with 
B6/SJL F1 hybrid females (Jackson Laboratories). As 
negative controls, 5XFAD mice were crossed to BACE1−/− 
mice [4] to generate 5XFAD;BACE1−/− mice. All animal 
work was done in accordance with Northwestern Univer-
sity IACUC approval.
Human tissue immunofluorescence
Human post-mortem brain tissue was obtained from three 
AD patients and three cognitively normal controls (Sup-
plementary Table S2) diagnosed at the Cognitive Neurol-
ogy and Alzheimer’s Disease Center with approval from 
the Northwestern University IRB. 40-μm floating sec-
tions of superior temporal gyrus were stained and imaged 
as described for murine tissue, except that primary and 
secondary antibody incubations were 48 h at 4 °C to 
improve antibody penetration, methoxy XO4 was added 
after secondary antibody incubation to label plaques, and 
0.2 % Sudan Black in 40 % ethanol was used to quench 
autofluorescence. Sections incubated in parallel without 
primary antibody were included as negative controls for 
autofluorescence and background binding of secondary 
antibody. A minimum of 10 plaques per case were imaged 
and analyzed on a Nikon A1 confocal microscope with a 
60× objective (NA 1.4) and NIS Elements software. Image 
acquisition settings were maintained the same between AD 
and control cases. We note that the βIII-tubulin antibody 
TuJ1 is very well characterized and produced the expected 
βIII-tubulin staining pattern in cognitively normal con-
trols (not shown) and in normal-appearing neuropil in AD 
cases (Fig. 3a, c), which served as positive controls. The 
no-primary antibody negative control produced only weak 
non-specific background staining in control and AD brain 
sections (not shown).
Murine tissue immunofluorescence
Mice were perfused with ice-cold PBS containing protease 
and phosphatase inhibitors (Calbiochem), brains harvested, 
and one hemibrain/mouse drop fixed in 4 % paraformalde-
hyde/PBS and cryopreserved in 30 % w/v sucrose/PBS for 
sectioning. The other hemibrain/mouse was dissected into 
cortex and hippocampus and flash frozen in LN2 for bio-
chemistry. 30-μm coronal or sagittal floating brain sections 
were cut and subjected to antigen retrieval for 1 h at 80 °C 
in 0.1 M sodium citrate pH 9 followed by 16 mM glycine 
in Tris-Buffered Saline with 0.25 % triton-X 100 (TBS-
T) and blocked in 5 % donkey serum in TBS-T. Sections 
were incubated overnight at 4 °C with primary antibodies 
listed in Supplementary Table 1, followed by secondary 
antibodies (donkey anti-mouse, rabbit or goat conjugated 
to Alexa 488, 568 or 647; Molecular Probes) used at the 
same concentration as primary antibody for 2–3 h at room 
temperature (except 4 °C overnight to improve penetration 
in the case of anti-tubulin antibodies) plus 300 nM DAPI. 
Sections incubated in parallel without primary antibody 
were included as negative controls for autofluorescence and 
background binding of secondary antibody. Sections were 
mounted with Prolong Gold (Molecular Probes) and images 
acquired on a Nikon A1 confocal microscope with a 60× 
objective (NA 1.4) and NIS Elements software. All image 
acquisition settings were maintained the same between 
genotypes (5XFAD;BACE1+/+ and 5XFAD;BACE1−/−). 
For all proteins whose plaque-associated co-localization 
with BACE1 was not previously published, 5–8 male and 
female 5XFAD mice at 5–6 or 9 months of age (Table S3) 
were analyzed, and 20–40 plaques were imaged for each 
antibody stain. For co-localization patterns of proteins with 
BACE1 that have been previously published (Table S4), we 
did not include additional mice but did confirm the origi-
nally reported staining patterns for βIII-tubulin (Fig. 3), 
MAP2 (Fig. 6), synaptophysin (Fig. 6), APP (Figs. 8, 9), 
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and Aβ/3D6 (Figs. 8, 9). We validated neoepitope antibod-
ies to APP cleavage products using brain sections from 
5XFAD;BACE1−/− mice (negative control). These sec-
tions were processed and imaged in parallel with brain 
sections from 5XFAD;BACE1+/+ mice. For other anti-
bodies, we considered normal-appearing neuropil regions 
distant from plaques to be an internal positive control, as 
well as normal-appearing regions of the stratum lucidum 
(Fig. 6, bottom row), which serves as a positive control for 
normal BACE1 localization and co-localization with other 
proteins.
Electron microscopy
5XFAD mouse brain tissue was prepared for electron 
microscopy as previously described [25]. Briefly, mice 
were anesthetized with isofluorane (Isothesia, Butler), per-
fused transcardially with 0.12 M PBS (pH 7.4) for 1 min, 
then a dilute aldehyde mixture (1 % paraformaldehyde, 
1.25 % glutaraldehyde, 0.02 mM CaCl2 in 0.1 M sodium 
cacodylate buffer) for 30 min, and a concentrated alde-
hyde mixture (2 % paraformaldehyde, 2.5 % glutaralde-
hyde, 0.04 mM CaCl2 in 0.1 M sodium cacodylate buffer) 
for 10 min. The brain was removed and placed in ice-cold 
concentrated fixative on a shaker at 4 °C overnight. The 
following day brain was bisected, rinsed 3× 20 min in 
0.12 M TBS and cut into 70 μm coronal sections. Sec-
tions were washed in 0.12 M phosphate buffer (PB) 3× 
10 min at 4 °C, treated with 2 % OsO4 in 0.12 M PB for 
1 h at 4 °C, and washed 3× 10 min in 0.12 M PB. The 
tissue was then dehydrated in graded ethanols and propyl-
ene oxide, infiltrated with 1:1 araldite:propylene oxide, 
flat embedded between aclar sheets and cured for 48 h at 
60 °C. Regions of interest were subdissected and re-embed-
ded as above. Serial ultrathin sections (65 nm) were cut, 
placed onto formvar-coated slotted grids, then stained with 
5 % aqueous uranyl acetate for 15 min, followed by Rey-
nold’s lead citrate (1.33 g lead nitrate, 1.76 g sodium cit-
rate, 30 ml distilled water, 8 ml of 1 N NaOH, then diluted 
to 50 ml) for 10 min, and rinsed in ultrapure dH2O. Images 
(7500–20,000×) were acquired on a JEOL 1200EX elec-
tron microscope (JEOL Ltd., IL, USA) from 10 to 30 serial 
sections. ImageJ software was used for processing image 
stacks of serial sections.
Immunoblotting
Frozen brain tissue was homogenized in RIPA buffer and 
20 μg of homogenate separated by 10 % tris–glycine 
SDS-PAGE. Protein was transferred onto 0.45 μm PVDF 
membrane, stained with 0.1 % Ponceau, and imaged. Blots 
were incubated with anti-APP antibody (6E10, Covance 
Sig-39300 1:2000) or anti-cathepsin D (Abcam # ab75852 
1:1000) followed by HRP-conjugated anti-mouse or anti-
rabbit secondary antibody (Vector Laboratories 1:10,000). 
Blots were visualized using chemiluminescence (Luminata 
Crescendo, Millipore), signals quantified using a Kodak 
Image Station 4000 R, normalized to Ponceau, densitomet-
ric analyses performed using Kodak 1D 3.6 image analysis 
software, and statistics analyzed in Prism GraphPad.
Statistical analyses
Statistical differences for immunoblot experiments were 
determined using two-tailed Student’s t test (GraphPad 
Prism Software, Inc., San Diego, CA, USA). Graphed data 
are presented as the mean ± SEM, and p < 0.05 was con-
sidered significant.
Results
Aβ42 causes neuritic beading and microtubule 
disruption in primary neurons in vitro
In addition to amyloid plaques and neurofibrillary tangles, 
other hallmark lesions of the Alzheimer’s disease brain 
include swollen, dystrophic neurites that surround amy-
loid plaques (reviewed in [9, 51]). Since these dystrophic 
neurites are predominantly found in very close proxim-
ity to, and often in contact with, plaques [25, 62] a neu-
rotoxic form of Aβ (e.g., oligomers) likely causes dystro-
phy formation. To test this hypothesis, we isolated primary 
cortical neurons from embryonic mice and exposed them 
to 1 μM of oligomeric Aβ42 for 72 h, then performed 
immunofluorescence microscopy for neuron-specific βIII-
tubulin. Aβ42-treated neurons displayed processes with 
numerous βIII-tubulin accumulations along their lengths 
resembling beads on a string, compared to vehicle-treated 
neurons (Fig. 1a). Neuritic beading was not likely associ-
ated with processes related to cell death caused by high 
concentrations of Aβ42, since we previously observed 
that 5 days of treatment with 1 and 2 μM Aβ42 oligom-
ers did not increase caspase 3 cleavages in primary neurons 
[49]. These beaded structures bore a striking resemblance 
to tubulin accumulations observed in dystrophic neurites 
around plaques in vivo (Fig. 3), suggesting a similar mech-
anism of generation. Our observation of tubulin accumula-
tion in beaded processes in Aβ42-treated cultured neurons 
is in agreement with extreme beading of primary neurons 
following 4 days of exposure to 15 μM Aβ42 [11].
Neuritic dystrophy and beading are observed in neu-
rons exposed to a variety of stressors and may be part of a 
regulated neurite degeneration pathway separate from cel-
lular apoptosis [10, 21, 28]. The presence of abnormal βIII-
tubulin accumulations in Aβ42-treated primary neurons 
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suggested that Aβ42 could disrupt microtubule networks, 
and that impaired axonal transport could be a specific and 
early effect of Aβ42 leading to serious neuronal and syn-
aptic dysfunction. To test this hypothesis, we followed 
microtubule dynamics in real time by live-cell imaging 
to determine if and when Aβ42 could cause microtubule 
disruption. We incubated primary neurons with Tubulin 
Tracker (Oregon Green-labeled taxol) that binds only to 
polymerized tubulin in microtubules, and then exposed 
the neurons to 10 μM Aβ42 oligomers (Fig. 1b) to model 
the potentially high Aβ42 oligomer concentrations in the 
immediate vicinity of amyloid deposits [29]. After 22 h 
of treatment, neuritic beading that strongly resembled the 
previously observed aberrant βIII-tubulin immunostaining 
pattern (Fig. 1a) was apparent in live Aβ42-treated Tubu-
lin Tracker-labeled neuron cultures (Fig. 1b), while vehi-
cle-treated neurons remained healthy with mostly smooth 
processes. These findings suggested that Aβ42 exposure 
results in microtubule disruption leading to abnormal tubu-
lin accumulation and neuritic beading in neurons.
To determine how early microtubule disruption and 
neuritic beading occur after exposure to Aβ42, we used 
spinning disk confocal microscopy to image live Tubu-
lin Tracker-labeled primary neurons continuously every 5 
Fig. 1  Oligomeric Aβ42 causes neurite beading and microtubule dis-
ruption in primary neurons. a Primary cortical neurons were cultured 
from e15.5 mouse embryos and after 9 days in vitro were exposed 
to 1 μM Aβ42 oligomers or vehicle. After 72 h, coverslips were 
fixed in 4 % paraformaldehyde, permeabilized, and stained with the 
antibody TuJ1 against βIII-tubulin (red) and DAPI (blue). Neurite 
beading is very prominent in Aβ42-treated cultures, while neurites 
appear smooth and unbeaded in vehicle-treated neurons. b Primary 
neurons were isolated as described in a, and after 12 days in vitro 
were exposed to 10 μM Aβ42 oligomers or vehicle. After 22 h of 
Aβ42 treatment, the fluorescent microtubule probe Tubulin Tracker 
was added to a final concentration of 250 nM for 30 min. Unfixed, 
live neurons were then imaged at ×20 using a Nikon Eclipse TS100 
microscope with NIS Elements software. Note that Aβ42-induced 
neurite beading visualized by Tubulin Tracker appears very similar to 
that observed with βIII-tubulin immunostaining in a, and occurs more 
rapidly with higher Aβ42 concentration. Taken together, these results 
strongly suggest that Aβ42 disrupts the organization of microtubules 
in neurons. Scale bars in all frames 50 μm
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min after 10 μM Aβ42 oligomer or vehicle treatment. We 
observed that noticeable microtubule disruption and bead-
ing occurred on neurites of primary neurons as early as 
3.5 h following Aβ42 treatment, while vehicle-treated cul-
tures appeared normal (Figs. 2a, S1). The very early appear-
ance of disrupted microtubules in beaded neurites sug-
gested that this is one of the primary ways in which Aβ42 
oligomers could impair neuronal function. Also, differen-
tial interference contrast microscopy indicated that most 
of the neurites with beads or aberrant microtubule organi-
zation were still continuous and intact, although morpho-
logically abnormal (Figs. 2a, S1). These results were highly 
reproducible, as they were representative of six individual 
experiments, all performed using separate primary neuron 
and Aβ42 preparations. We also observed a greater overall 
decrease in Tubulin Tracker fluorescence after 3 h in the 
Aβ42-treated neurons compared to vehicle (Fig. 2b), sug-
gesting that Aβ42 causes microtubule depolymerization. To 
limit photodamage, we performed an identical live-imaging 
experiment, except capturing an image once every hour 
for 6 h, and observed even more striking neuritic beading 
and microtubule disruption in Aβ42-treated neurons, while 
vehicle-treated neurons showed very little change (Fig. 2c).
Aβ42 oligomer concentrations in the range of 1–10 μM 
induce cell death in primary neuron culture (reviewed in 
[16]). To determine whether neuritic beading and microtu-
bule disruption were the results of Aβ42-induced cell death 
processes, we repeated Tubulin Tracker labeling of primary 
neurons followed by Aβ42 treatment for 3.5 h, then added 
propidium iodide to label the nuclei of dead cells (Fig. S1). 
Although we noted Aβ42-induced neuritic beading and 
microtubule disruption (Fig. S1a), the percentage of live 
cells as measured by absence of propidium iodide uptake 
was identical for both Aβ42-treated and vehicle control 
neurons (Fig. S1b). This result demonstrates that neuritic 
beading and microtubule disruption precede the induction 
of cell death in Aβ42-treated primary neurons.
The Aβ42-induced reduction and aberrant spatial dis-
tribution of microtubules in neurites suggested that micro-
tubule-based transport would be impaired in Aβ42-treated 
primary neurons. It has also been reported that trafficking of 
BDNF [44] mitochondria [70], and other axonal cargo [57] 
is impaired by Aβ, so we hypothesized BACE1 transport 
may be affected as well. To test this hypothesis, we trans-
fected primary neurons with BACE1-YFP and neuropeptide 
Y-mCherry (NPY-mCherry) fusion constructs, treated with 
10 μM Aβ42 oligomers or vehicle, and performed live-cell 
imaging and kymograph analysis to assess vesicular move-
ment in neurites. We observed that the proportion of motile 
BACE1-YFP and NPY-mCherry puncta was decreased 
in neurites of Aβ42-treated neurons, compared to vehicle 
(Fig. S2). We infer that the effect of Aβ42 on trafficking 
in neurites is not limited to BACE1-containing vesicles, as 
the movement of NPY-mCherry puncta was also decreased. 
Taken together, our results suggest that Aβ42 causes micro-
tubule depolymerization and network disruption, leading 
to neuritic beading and impaired microtubule-based axonal 
transport in neurons.
Tubulin is aberrantly localized and microtubules 
are disrupted in peri‑plaque presynaptic dystrophic 
neurites in vivo
In both AD and APP transgenic mouse brains, BACE1 
accumulates in swollen presynaptic dystrophic neurites 
that surround amyloid plaques in close proximity [25, 85, 
86]. To gain insight into the mechanism of Aβ-induced 
BACE1 elevation in peri-plaque dystrophies and the 
potential role of microtubules, we performed immuno-
fluorescence staining of superior temporal gyrus from 
AD patients and cognitively normal controls (Table S2) 
with antibodies against BACE1 and neuron-specific βIII-
tubulin, as well as methoxy XO4 to label fibrillar amyloid 
deposits. As we have previously reported [25, 86], in AD 
brain BACE1 immunoreactivity was elevated in dystrophic 
neurites in a halo pattern immediately surrounding the 
methoxy XO4-positive amyloid plaque core. Interestingly, 
we observed a striking reduction of βIII-tubulin signal 
within the BACE1-positive peri-plaque halo, while the pat-
tern of βIII-tubulin immunoreactivity seemed unaffected 
in nearby normal-appearing neuropil (Fig. 3a, first two 
columns; Fig. S3, first column) and in cognitively normal 
controls (not shown). To determine the quantitative rela-
tionships between BACE1 and βIII-tubulin immunoreac-
tivities within the peri-plaque halo, we calculated the ratio 
of BACE1 to βIII-tubulin immunofluorescence intensities 
in dystrophic neurites (defined by high BACE1 signal) 
around plaques and in regions of normal neuropil distant 
from plaques for the AD cases (Fig. 3b). Importantly, we 
observed that the peri-plaque BACE1:βIII-tubulin ratio 
was significantly elevated (Fig. 3b, first two panels). We 
also generated intensity profiles of BACE1 and βIII-
tubulin immunofluorescence signals through the plaque, 
and generally found an inverse relationship between 
BACE1 and βIII-tubulin intensities, such that high BACE1 
signal typically occurred in areas of low βIII-tubulin 
intensity (Fig. 3c, first two columns). In cognitively nor-
mal controls, no plaques, and hence no areas of elevated 
BACE1 or loss of βIII-tubulin, were observed (not shown). 
These results confirm and extend our initial observation 
of decreased βIII-tubulin staining around plaques in AD 
[86]. Moreover, they suggest that reduced tubulin level, 
and hence low microtubule density, in dystrophic regions 
surrounding plaques is a pathologic feature of AD that is 
the consequence of short-range Aβ toxicity to neurites, and 
may have a role in BACE1 accumulation.
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Fig. 2  Microtubule disruption in primary neurons is an early response 
to oligomeric Aβ42. Primary cortical neurons were cultured as in 
Fig. 1, and after 12 days in vitro, were labeled for 30 min with 250 nM 
Tubulin Tracker, rinsed, and then exposed to 10 μM Aβ42 oligomers 
or vehicle. Live imaging on an Andor spinning disk confocal micro-
scope began 30 min after addition of Aβ42. a Fluorescence and dif-
ferential interference contrast (DIC) images were acquired every 5 
min for 3 h. Neurite beading, microtubule accumulation in varicosi-
ties (arrowheads), and microtubule fragmentation (arrows) in neurites 
were present 3.5 h after Aβ42 addition, in the absence of significant cell 
death or BACE1 elevation [49]. In contrast, the morphology of vehi-
cle-treated neurons was unaffected, with the exception of a moderate 
decrease of fluorescence intensity. DIC imaging revealed that neurites 
of Aβ42-treated neurons were intact and continuous, even though they 
exhibited beading and microtubule fragmentation, indicating that the 
observed microtubule disruption was not the result of physical degen-
eration of neurites. Insets show higher magnification images of the 
boxed region of the Aβ42-treated culture to accentuate varicosity for-
mation and microtubule fragmentation. b The ratios of Tubulin Tracker 
fluorescence intensity (Int.) at 3.5 h (hours) to that at 0.5 h after Aβ42 
treatment were calculated for 46 image fields from two separate experi-
ments and averaged for Aβ42-treated and vehicle-treated neurons. 
Overall Tubulin Tracker fluorescence intensity decreased in neurons 
over time due to photo-bleaching, as indicated by fluorescence intensity 
ratios below 1. Nevertheless, the Tubulin Tracker fluorescence intensity 
ratio for Aβ42-treated neurons showed a small but highly significant 
decrease compared to vehicle treatment (p = 0.004), suggesting micro-
tubule depolymerization and reduced stability of microtubule networks 
after only 3.5 h of Aβ42 exposure. Error bars SEM; **, p < 0.01. c To 
investigate longer Aβ42 treatment times and minimize photo-bleach-
ing, primary neuron cultures were prepared as above and images col-
lected once every 60 min for 6 h. Neurite beading, aberrant microtubule 
localization, and microtubule fragmentation were even more prevalent 
and pronounced in neurons after 6.5 h compared to 3.5 h of Aβ42 treat-
ment, while vehicle-treated neurites continued to appear normal. Scale 
bars 20 μm for all images in a, c
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Post-mortem AD brain samples represent end-stage dis-
ease and thus provide limited information about pathogen-
esis. To gain insight into the development of Aβ-induced 
dystrophic neurites, we turned to our 5XFAD mouse model 
of amyloid pathology [40]. Our previous work showed that 
brains of AD patients and 5XFAD mice have elevated lev-
els of BACE1 that accumulate in dystrophic presynaptic 
neuronal structures (likely axons and terminals) in a halo 
that surrounds the amyloid deposit [86]. Taken together, 
these and other data suggest that the 5XFAD mouse is a 
faithful model of BACE1 elevation in AD.
To assess the distributions of tubulin and BACE1 around 
amyloid deposits in our AD mouse model, we immu-
nostained brain sections from five different 5- to 6-month-
old 5XFAD mice with antibodies directed against specific 
isoforms of tubulin, including neuron-specific βIII-tubulin, 
acetylated α-tubulin, and polyglutamylated tubulin (Fig. 3a, 
third, fourth and fifth columns, respectively; Figs. S3, S4). 
BACE1 immunoreactivity was concentrated in a halo sur-
rounding the core of the amyloid deposit, as previously 
reported [25, 85, 86]. Interestingly, similar to human AD, 
we observed that βIII-tubulin immunostaining was largely 
absent in BACE1-positive peri-plaque dystrophies. The 
βIII-tubulin signals that did occur in the peri-plaque halo 
appeared as amorphous accumulations with a staining pat-
tern complementary to that of BACE1, i.e., regions of high 
βIII-tubulin intensity generally showed low BACE1 signal 
and vice versa. Acetylated and polyglutamylated isoforms 
of tubulin showed similarly reduced patterns of immu-
nostaining in the peri-plaque halo. Additionally, we meas-
ured peri-plaque BACE1:tubulin ratios and intensity pro-
files for 5XFAD amyloid deposits (Fig. 3b, c) and found 
increased ratios and inverse relationships between BACE1 
and tubulin isoforms, similar to our results for human AD 
plaques. We note that the peri-plaque human and mouse 
tubulin and BACE1 immunoreactivity patterns are similar 
but not identical, probably because mouse deposits are at 
most a few months old while human plaques are possibly 
many years old. At the end-stage of disease in post-mortem 
AD brain, there are very few, if any neurites near plaques 
that are not severely degenerated, thus potentially explain-
ing the lower intensities of BACE1 and tubulin immu-
nostaining in peri-plaque dystrophies of human AD com-
pared to 5XFAD mouse.
The reduction in tubulin isoforms in 5XFAD BACE1-
positive dystrophies suggested that microtubules are 
decreased, disorganized, or disrupted in presynaptic dys-
trophic neurites near amyloid deposits. To investigate this 
possibility at an ultrastructural level, we examined ultrathin 
sections of 5XFAD mouse brain by electron microscopy 
(EM). We found swollen dystrophic neurites in abundance 
in close proximity or virtually contacting amyloid depos-
its (Fig. 4a). We confirmed the close physical association 
between BACE1-positive dystrophies and amyloid deposits 
in 3D reconstructions of multi-photon confocal microscopy 
images of live brain slices of BACE1-YFP;5XFAD multi-
transgenic mice (Supplementary Text; Fig. S5, Videos S1, 
S2). By BACE1 immuno-EM, we previously reported that 
dystrophies surrounding plaques are engorged with large 
BACE1-negative electron-dense multi-lamellar vesicles and 
smaller BACE1-positive electron-translucent vesicles [25]. 
Here, by EM we found dystrophies that were definitively 
identified as axons, as indicated by the presence of myelin 
sheaths (Fig. 4b–f). Importantly, we found occasional EM 
Fig. 3  Tubulin isoforms are aberrantly localized in BACE1-positive 
peri-plaque dystrophic neurites in vivo. a Post-mortem brain sections 
of superior frontal gyrus from three AD patients and three cognitively 
normal controls were stained with antibodies against BACE1 (red) 
and βIII-tubulin (green), and methoxy XO4 (blue) to label amyloid 
deposits. Representative plaques from two cases (AD 14–190 and AD 
11–193, Columns 1–2) are shown; additional examples in Fig. S2. 
Cognitively normal controls were negative for plaques, as expected 
(not shown). As previously reported [86], BACE1 immunostaining 
was observed in a halo of dystrophic neurites surrounding individual 
plaques. In contrast, βIII-tubulin immunostaining was almost entirely 
absent in peri-plaque BACE1-positive dystrophies. Non-dystrophic 
neuropil in areas adjacent to plaques exhibited normal intensities 
and patterns of βIII-tubulin immunostaining. Some red fluorescence 
(white arrows) represents non-specific background from blood vessels. 
Brain sections from the aggressive amyloid 5XFAD mouse model 
were stained with antibodies against BACE1 (red) and βIII-tubulin, 
acetylated α-tubulin or polyglutamylated tubulin (green). Representa-
tive 5XFAD amyloid deposits are shown (Columns 3–5), with plaque 
cores marked by asterisks; additional examples in Fig. S2. Similar to 
human AD, BACE1 accumulated in peri-plaque dystrophic neurites 
in 5XFAD brain sections. Additionally, the different tubulin isoforms 
were generally reduced in dystrophic halos around plaques, although 
tubulins often occurred in amorphous accumulations that showed little 
co-localization with BACE1 immunostaining. Scale bars in all frames 
10 μm. b Immunofluorescence intensities of BACE1 and tubulin iso-
forms (as indicated at top of each column) in peri-plaque dystrophic 
neurites were measured and BACE1/tubulin intensity ratios calcu-
lated and compared to those in normal-appearing regions of neuropil 
within the same frame (Supplementary Methods). For human tissue, 
16 dystrophies and corresponding non-dystrophic regions were meas-
ured per case. For murine tissue, BACE1/tubulin isoform ratios were 
determined for 11–20 BACE1-positive dystrophic regions and a cor-
responding number of nearby neuropil areas. BACE1/tubulin ratios 
for AD 14–190 and AD 11–193 (Panels 1 and 2, respectively) and 
5XFAD mice (Panels 3–5) are shown. While there was substantial 
variation for dystrophic neurites, BACE1/tubulin intensity ratios for 
dystrophies were significantly elevated compared to those for nor-
mal neuropil for both AD cases and 5XFAD mice. Error bars SEM; 
***p < 0.001. c The quantitative relationships between BACE1 and 
tubulin isoform immunofluorescence intensities by another method, 
intensity profiles as a function of distance across the plaque were 
generated (Supplementary Methods). Representative plaques are 
shown (upper row) for AD 14–190 and AD 11–193 (Panels 1 and 2, 
respectively) and 5XFAD mice (Panels 3–5). White line indicates path 
through plaque from which the intensity profiles were generated (bot-
tom row). Note the inverse relationships between BACE1 and tubulin 
intensities as a function of distance across the plaque in each case. 
Taken together, these results suggest that tubulin, and hence microtu-
bules, is reduced and/or mis-localized in peri-plaque dystrophic neur-
ites. AU arbitrary units. Scale bars in all frames 10 μm
◂
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series displaying normal-appearing axons with dense micro-
tubule bundles that enter a dystrophic region within which 
microtubules are strikingly absent, reduced in length, or 
dramatically disorganized (Fig. 4c–f). These data suggest 
that in human AD and in amyloid pathology mouse models, 
peri-plaque dystrophic axons are deficient in normal func-
tional microtubule networks for axonal transport. Vesicles 
may enter but cannot transit or exit dystrophic regions due 
to absence of microtubules, which could explain the dra-
matic accumulation of BACE1 around plaques.
Microtubule motor proteins are aberrantly localized 
in BACE1‑positive peri‑plaque dystrophic neurites
Recent work has linked mutations in various proteins 
of the dynein–dynactin complex required for retrograde 
axonal transport to neurodegenerative disease in humans 
and mouse models [43]. If microtubule networks are dis-
rupted in dystrophies around plaques, we reasoned that the 
microtubule motor proteins that move along them carrying 
cargo from the terminals back to the cell body could also 
be mis-localized, compounding the impaired removal of 
vesicles from dystrophic axons and terminals. This could 
lead to decreased turnover of proteins that are preferen-
tially localized to presynaptic terminals, like BACE1 [25, 
86]. To determine the localization pattern of microtubule 
motor proteins in peri-plaque dystrophies, we performed 
immunofluorescence microscopy of coronal brain sections 
from five individual 5- to 6-month-old 5XFAD mice using 
antibodies directed against cytoplasmic dynein intermedi-
ate chain (DIC), two subunits of dynactin (p150glued and 
dynamitin), and kinesin heavy chain (Figs. 5, S3, S4). DIC 
Fig. 4  Microtubules are strikingly absent in peri-plaque dystrophic 
axons. 5XFAD brain tissue was prepared for electron microscopy 
(EM) and assessed ultrastructurally for the presence of microtubules in 
peri-plaque dystrophic axons. a As previously reported [25], electron 
microscopy of 5XFAD brain revealed amyloid plaques (p) surrounded 
by dystrophic neurites (representative examples outlined in blue) filled 
with electron-dense multi-lamellar vesicles, possibly autophagic inter-
mediates. b EM of a transverse section through a pair of dystrophic 
myelinated axons filled with multi-lamellar vesicles. Note that the 
lower portion of the axon on the left has lost its myelin sheath. c–f EM 
of serial ultrathin sections occasionally revealed series of longitudinal 
sections through dystrophic axons near amyloid plaques. Shown is 
such a series of a peri-plaque dystrophic myelinated axon with a por-
tion of normal axon appearing on the left side of the dystrophy. Intact, 
continuous microtubules (yellow shading) are present in the morpho-
logically normal part of the axon, but then microtubules become dis-
organized and mostly disappear within the dystrophic region. Note the 
dark outline of the surrounding myelin sheath, definitively confirming 
axonal identity. These ultrastructural images provide direct evidence 
that microtubules are disrupted and largely absent in peri-plaque dys-
trophic regions of axons. Images are spaced ~200 nm apart. f Higher 
magnification of rectangle in e. Scale bars 1 μm
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is a component of the retrograde microtubule motor, and 
while we observed some DIC staining in BACE1-posi-
tive dystrophic neurites, it was quite low compared to the 
amount of potential cargos such as BACE1 that accumu-
late in dystrophies (Figs. 5a, S3, S4). p150glued is required 
to initiate retrograde transport from the axon terminal [32, 
37], stabilize microtubules in axons [30], and improve pro-
cessivity of dynein [27, 35]. Importantly, p150glued was 
diminished in BACE1-positive peri-plaque dystrophies 
compared to normal surrounding neuropil (Figs. 5b, S3, 
S4), suggesting a deficiency of functional and active retro-
grade dynein–dynactin complexes in these dystrophies. In 
contrast, dynamitin staining was noticeably increased in 
some, but not all, BACE1-positive peri-plaque dystrophies 
(Figs. 5c, S3, S4). Dynamitin tethers the cargo-binding 
domain of dynactin to the microtubule and dynein-binding 
domain through its interactions with Arp1 and p150glued, 
respectively [5]. The increased dynamitin in peri-plaque 
dystrophies suggested that it may be trapped in either free 
form or in complexes with adaptor proteins and cargo, but 
lacking p150glued, dynamitin cannot be attached to dynein 
and transported with cargo back toward the soma. Disrup-
tion of microtubule networks in peri-plaque dystrophic 
neurites would also be predicted to have an effect on anter-
ograde axonal transport by kinesins and cause kinesin mis-
localization. Our immunofluorescence microscopy analy-
sis showed that, similar to dynamitin, kinesin heavy chain 
accumulated in dystrophies surrounding plaques (Figs. 5d, 
S3, S4), supporting our hypothesis that peri-plaque presyn-
aptic dystrophic neurites are deficient in microtubules and 
exhibit mis-localized microtubule motor proteins, condi-
tions that would impair axonal transport.
Fig. 5  Microtubule motor proteins are aberrantly localized in 
BACE1-positive peri-plaque dystrophic neurites. Sections from 
5XFAD mouse brains were stained with antibodies against BACE1 
(red) and various components of the dynein–dynactin retrograde 
transport complex, dynein intermediate chain (green, a), p150glued 
(green, b), dynamitin (green, c), or the anterograde motor protein 
kinesin heavy chain (green, d). Representative amyloid deposits are 
shown; additional examples in Figs. S3 and S4. Dynein intermediate 
chain and p150glued were reduced in peri-plaque BACE1-positive 
dystrophic neurites, while dynamitin and kinesin heavy chain tended 
to accumulate in dystrophies and showed partial but limited co-local-
ization with BACE1. These results together with evidence of micro-
tubule disruption strongly suggest that axonal transport is impaired in 
dystrophic regions of peri-plaque axons. DAPI staining (blue) identi-
fied nuclei and autofluorescence of amyloid plaque cores (marked by 
asterisks). Scale bars 10 μm (a, b, d) and 20 μm (c)
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BACE1‑positive peri‑plaque dystrophies are 
presynaptic, but lack components of functional 
synapses
To further characterize BACE1-positive peri-plaque 
dystrophic neurites in 5XFAD brain sections, we per-
formed immunofluorescence microscopy with antibodies 
directed against BACE1 and several other neuronal pro-
teins (Figs. 6, S3, S4), confirming that accumulation in 
dystrophies is specific to certain proteins but not others. 
Synaptophysin and bassoon, both presynaptic proteins, 
show strong co-localization with BACE1 in the stratum 
lucidum, the axon terminals of the mossy fiber pathway 
in the hippocampus (Fig. 6a, b; bottom row), confirming 
Fig. 6  BACE1-positive peri-plaque dystrophies accumulate the pre-
synaptic protein synaptophysin and the lysosomal protease cathepsin 
D, but lack the active zone protein bassoon. Sections from 5XFAD 
mouse brains were stained with antibodies against BACE1 (red) and 
active zone protein bassoon (green, a), presynaptic protein synap-
tophysin (green, b), somatodendritic marker MAP2, (green, c), or 
lysosomal protease cathepsin D (green, d). Representative amyloid 
deposits are shown; additional examples in Figs. S3 and S4. Both 
bassoon and synaptophysin co-localized extensively with BACE1 in 
presynaptic terminals in the stratum lucidum (bottom row), but bas-
soon and synaptophysin were absent and enriched in peri-plaque dys-
trophies, respectively (top row). The somatodendritic protein MAP2, 
which did not co-localize with BACE1 in the stratum lucidum (bot-
tom row), was absent in peri-plaque dystrophies (top row). The lyso-
somal protease cathepsin D was found in neuronal soma as expected 
and did not co-localize with BACE1 in stratum lucidum (bottom 
row). However, cathepsin D tended to accumulate in some dystro-
phies, indicating aberrant localization of lysosomes in peri-plaque 
dystrophic neurites. These results suggest that BACE1-positive 
peri-plaque dystrophies are largely presynaptic axons and terminals, 
although dystrophic terminals are unlikely to have active synapses as 
they lack bassoon. DAPI staining (blue) identified nuclei and autoflu-
orescence of amyloid plaque cores (marked by asterisks). Scale bars 
10 μm in all frames except for the bottom row, which is 20 μm
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our previous results that BACE1 is normally localized in 
the presynaptic terminal [25]. As we have reported before 
[25, 86], and was recently confirmed [15, 50], many peri-
plaque dystrophies appear to be axonal in origin, showing 
accumulations of the presynaptic protein synaptophysin 
(Fig. 6b), and a conspicuous absence of the somatoden-
dritic marker MAP2 (Fig. 6c), which does not co-local-
ize with BACE1 in the stratum lucidum (Fig. 6c; bottom 
panel). Surprisingly, given its strong co-staining with 
BACE1 in normal tissue of the stratum lucidum, bassoon 
appears to be entirely absent from peri-plaque dystrophies 
(Fig. 6a). Since bassoon is a well-established marker of 
synaptic active zones (reviewed in [6]), its absence from 
peri-plaque dystrophies indicates a lack of functional 
synapses in these regions. The toxic effect of amyloid 
plaques on synapses seems to be quite local, as the immu-
nofluorescence signal for bassoon outside the immediate 
peri-plaque halo of the dystrophies appears as a normal 
punctate pattern. This is supported by other APP trans-
genic mouse studies showing that PSD95 was reduced by 
60 % in the halo of oligomeric Aβ42 surrounding plaques, 
while 50 μm from the plaque it was found at normal lev-
els [29].
Immature pro‑cathepsin D accumulates in 5XFAD 
mouse brain
Cathepsin D is found in lysosomes, which normally local-
ize to a peri-nuclear region of the soma rather than axon 
terminals, and cathepsin D does not co-localize with 
BACE1 in normal-appearing regions of the 5XFAD stra-
tum lucidum (Fig. 6d, bottom panel). Although cathepsin 
D appeared somewhat elevated in 5XFAD BACE1-posi-
tive peri-plaque dystrophies, the patterns of cathepsin D 
and BACE1 localization did not overlap as extensively 
as those of synaptophysin and BACE1 (Figs. 6d, S3, S4). 
BACE1 is normally degraded through lysosomal path-
ways [26, 60], and thus presynaptic BACE1 is depend-
ent on retrograde transport to the cell body for turnover. 
Early lysosomes, identified by Lamp1 expression, are 
found in dystrophic neurites [15, 25] but are deficient in 
cathepsins [15]. These studies together with our results 
suggest that microtubule disruption and motor protein 
mis-localization impair retrograde transport and hence 
lysosomal maturation, ultimately resulting in reduced 
degradation of BACE1 and other proteins in peri-plaque 
dystrophic neurites. The cathepsin D antibody that we 
used for our immunolocalization analysis (Fig. 6d) recog-
nizes the C-terminus of both 43 kDa pro-cathepsin D and 
28 kDa cathepsin D heavy chain, precluding our ability 
to determine whether peri-plaque cathepsin D was mature 
(active) or immature (inactive). To distinguish and quan-
tify mature and immature forms of cathepsin D, we per-
formed immunoblot analysis of brain homogenates from 
6-month-old 5XFAD and non-transgenic mice using the 
cathepsin D antibody (Fig. 7a). We observed that 5XFAD 
brains had significantly increased levels of immature 
pro-cathepsin D compared to brains of non-transgenic 
Fig. 7  Levels of immature pro-cathepsin D are increased in 5XFAD 
mouse brain. a Cortices from 6-month 5XFAD (+) or non-transgenic 
(−) mice were homogenized and subjected to immunoblot analysis 
using antibodies against human APP (top panel; antibody 6E10) and 
the C-terminus of the lysosomal protease cathepsin D (CatD), which 
recognizes both immature (inactive) pro-CatD and mature (active) 
CatD heavy chain (middle panel). Ponceau S staining of the immu-
noblot was used to control for protein loading (bottom panel). Note 
that 43-kDa immature pro-CatD bands are more intense than 28 kDa 
mature CatD heavy chain bands, especially in 5XFAD cortices. b 
Band intensities from the immunoblot in a were quantified and nor-
malized to total protein as determined by ponceau S staining intensity 
in respective lanes and then displayed as percentage of non-trans-
genic (non-Tg) control. Note that 5XFAD cortex levels of pro-CatD 
were nearly twofold higher than those in non-Tg cortex, while levels 
of CatD heavy chain were not significantly changed, suggesting that 
lysosomal maturation is impaired in 5XFAD brains. Error bars SEM; 
**p < 0.01; NS not significant
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littermates, while 5XFAD levels of mature cathepsin 
D heavy chain were unchanged (Fig. 7b). This result is 
consistent with the notion of impaired maturation of lys-
osomes in the brains of 5XFAD mice, which might con-
tribute to accumulation of BACE1 and other proteins in 
peri-plaque dystrophic neurites.
BACE1‑positive peri‑plaque dystrophic neurites are 
sources of increased production of BACE1‑cleaved APP 
fragments and Aβ42
Our observations of BACE1 accumulation around plaques 
led us to the hypothesis that elevated levels of BACE1, APP 
Fig. 8  Neoepitope antibodies recognize BACE1-cleaved APP 
and Aβ but not full-length APP in vivo. Sagittal brain sections of 
5XFAD;BACE1+/+ and 5XFAD;BACE1−/− mice were immu-
nostained with neoepitope antibodies to a the free C-terminus of 
BACE1-cleaved APP ectodomain ending in the Swedish mutation, 
sAPPβ (antibody ANJJ [45, 46], green), b the free N-terminus of 
BACE1-cleaved Aβ (antibody 3D6 [23], red), or c the free C-ter-
minus of γ-secretase-cleaved Aβ42 (green). Sections were also co-
immunostained with an antibody recognizing full-length APP (anti-
body Karen [64], red), then imaged by confocal microscopy. All three 
neoepitope immunoreactivities were present in soma (arrows), and 
processes in the case of sAPPβ (arrowheads), of pyramidal neurons 
in the cortex of 5XFAD;BACE1+/+ mice, while none were detected 
in 5XFAD;BACE1−/− cortex, despite overexpression of transgenic 
APP in pyramidal neurons of both genotypes. These data confirm 
that ANJJ, 3D6, and Aβ42 antibodies are selective for their respective 
neoepitopes and do not cross-react to full-length APP. DAPI staining 
(blue) identified nuclei and autofluorescence of amyloid deposit cores 
(marked by asterisks). Note that amyloid deposits are completely 
lacking in 5XFAD;BACE1−/− cortex, as previously reported [41]. 
Scale bars 10 μm (b), 20 μm (a)
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[25, 86], and PS1 [81] found in peri-plaque dystrophic neu-
rites would cause increased BACE1 processing of APP and 
Aβ production, thus exacerbating AD pathogenesis. How-
ever, direct evidence that elevated BACE1 cleaves APP 
and leads to increased Aβ formation in dystrophic neurites 
has been lacking. To address this question, we made use of 
several antibodies specific to neoepitopes of APP-derived 
fragments revealed by BACE1 and γ-secretase process-
ing. BACE1 cleavage of APP generates two products, the 
N-terminal soluble APP ectodomain fragment, sAPPβ, and 
the membrane bound C-terminal fragment, C99. The anti-
body ANJJ [45] recognizes the free C-terminus of sAPPβ 
created by BACE1 processing of APP with the Swedish 
familial AD mutation [38], which is expressed in 5XFAD 
mice [40]. To validate ANJJ for tissue immunostaining and 
verify that it does not recognize unprocessed full-length 
APP, we co-stained sagittal brain sections from 9-month-
old 5XFAD;BACE1+/+ and 5XFAD;BACE1−/− bigenic 
mice with ANJJ and an antibody to an N-terminal epitope 
of full-length APP [64] and performed immunofluores-
cence confocal microscopy (Fig. 8). We observed punctate 
sAPPβ immunoreactivity of ANJJ in the soma and pro-
cesses of 5XFAD;BACE1+/+ large pyramidal neurons in 
the cortex (Figs. 8a, upper panels; S4), the primary cells 
that express the 5XFAD transgenes in the brain [40]. The 
punctate intracellular immunostaining pattern for sAPPβ 
was expected, since BACE1 cleaves APP in endosomes 
[45, 66] to create the sAPPβ neoepitope and release the 
soluble APP ectodomain into the endosome lumen for 
eventual secretion into the extracellular milieu. The immu-
noreactivity of full-length APP exhibited a wider spatial 
distribution in the neuron compared to that of sAPPβ, indi-
cating cell surface localization in addition to intracellular 
labeling. In contrast, sAPPβ immunosignal was completely 
absent in 5XFAD;BACE1−/− brain sections (Fig. 8a, 
lower panels), indicating the absence of the sAPPβ free 
C-terminal neoepitope as expected for BACE1-deficient 
mice [34], even though full-length APP immunoreactiv-
ity throughout the neuron was similar to that observed in 
5XFAD;BACE1+/+ sections. These results demonstrate 
conclusively that the ANJJ antibody only recognizes the 
BACE1-cleaved sAPPβ C-terminal neoepitope and does 
not cross-react to full-length APP in brain sections.
We also performed immunofluorescence microscopy on 
5XFAD;BACE1+/+ and 5XFAD;BACE1−/− brain sec-
tions incubated with antibodies recognizing neoepitopes 
on the free N-terminus of BACE1-cleaved Aβ (3D6) [23] 
and the free C-terminus of γ-secretase-cleaved Aβ end-
ing in amino acid 42 (Aβ42), co-stained with the full-
length APP antibody (Fig. 8b). As with sAPPβ immu-
nosignal, we observed intraneuronal 3D6 and Aβ42 
neoepitope immunostaining only in large pyramidal corti-
cal neurons of 5XFAD;BACE1+/+ mice, while those of 
5XFAD;BACE1−/− mice were completely devoid of either 
3D6 or Aβ42 neoepitope immunoreactivities (Fig. 8b) even 
though they showed robust full-length APP labeling. Taken 
together, these results fully validate the 3D6 and Aβ42 
neoepitope antibodies for tissue immunostaining and con-
firm that they do not label full-length APP.
Next, using our validated neoepitope antibodies we 
sought to determine whether elevated BACE1 in peri-
plaque dystrophies was associated with increased BACE1 
processing of APP and Aβ generation. Importantly, sagittal 
brain sections from 5- to 6-month and 9-month-old 5XFAD 
mice co-incubated with sAPPβ neoepitope and BACE1 
antibodies showed robust punctate sAPPβ immunoreac-
tivity, likely representing endosomal localization, within 
peri-plaque dystrophies that significantly co-localized with 
BACE1 immunosignal (Figs. 9a, S4). sAPPβ immunore-
activity was very intense in peri-plaque dystrophies, com-
pared to the very low sAPPβ immunosignal in the surround-
ing neuropil, indicating that BACE1 processing of APP was 
dramatically increased in the BACE1-positive dystrophic 
neurites near amyloid deposits. We noted that peri-plaque 
dystrophies exhibited variable levels of transgenic sAPPβ 
immunoreactivity, presumably because the Thy1 transgene 
promoter is expressed in some, but not all, cortical neu-
rons [36]. Similar to the sAPPβ immunostaining pattern, 
we observed increased punctate 3D6 and Aβ42 neoepitope 
immunosignals that co-localized significantly with BACE1 
immunoreactivity in peri-plaque dystrophies (Figs. 9b, c, 
respectively; S4), suggesting that BACE1 accumulation 
elevated Aβ production. Although 3D6 and Aβ42 immu-
nosignal intensities in dystrophies were weaker than those 
in amyloid deposits, they were obviously elevated com-
pared to surrounding neuropil, especially at higher magni-
fications (right panels, 9b, c). Additionally, sAPPβ and 3D6 
neoepitope immunoreactivities co-localized significantly 
in peri-plaque dystrophies (Fig. 9d). Co-immunostaining 
of 5XFAD brain sections with full-length APP and BACE1 
antibodies confirmed that APP and BACE1 accumulate 
together in peri-plaque dystrophies (Fig. 9e), implicating 
both in plaque progression.
Taken together, our results suggest that elevated BACE1 
in dystrophic neurites around plaques is associated with 
increased BACE1 cleavage of APP and Aβ generation. The 
presence of neoepitope N-terminal and C-terminal APP 
processing products in peri-plaque dystrophies strongly 
supports the hypothesis that BACE1 and γ-secretase are 
active in dystrophies, although we cannot formally exclude 
the possibility that APP processing occurs elsewhere in 
the cell followed by APP product trafficking and accumu-
lation in dystrophies. Additionally, our results show that 
peri-plaque dystrophic neurites accumulate Aβ42, which 
if released into the extracellular space could contribute to 
plaque growth and further neuritic dystrophy.
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Discussion
In this study, we provide evidence that Aβ mediates micro-
tubule disruption and microtubule-based transport impair-
ment leading to dystrophic neurite formation, BACE1 
accumulation, increased BACE1 cleavage of APP and Aβ 
production. Primary neurons treated with Aβ42 oligom-
ers exhibited disrupted microtubules, neuritic beading, and 
reduced BACE1-YFP trafficking after only a short Aβ42 
exposure in vitro. In the 5XFAD mouse model of amy-
loid pathology, presynaptic dystrophic neurites surround-
ing plaques showed BACE1 accumulation that correlated 
with aberrant localization patterns of tubulins, microtu-
bule motor proteins, and synaptic and cell body proteins. 
Tubulin was largely absent from human AD and 5XFAD 
BACE1-positive peri-plaque dystrophies and showed 
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increased BACE1:tubulin ratios and inverse relationships 
between BACE1 and tubulin. Although 5XFAD peri-plaque 
dystrophic neurites accumulated the lysosomal protease 
cathepsin D, it largely appeared to be immature pro-cath-
epsin D, suggesting that impaired lysosomal maturation 
correlates with BACE1 accumulation. By EM, peri-plaque 
dystrophic axons lacked intact microtubules, consistent 
with reduced tubulin by immunofluorescence microscopy. 
Remarkably, the toxic effects of amyloid on dystrophies 
were highly localized to the immediate vicinity of the 
plaque, with neighboring axons and terminals appearing 
normal. Multi-photon confocal microscopy 3D-reconstruc-
tions of live 5XFAD;BACE1-YFP brain slices invariably 
showed physical contact between BACE1-YFP-positive 
dystrophies and amyloid deposits. Most importantly, peri-
plaque dystrophies displayed BACE1 and APP accumula-
tion, increased BACE1 cleavage of APP, and elevated Aβ42 
generation.
Taken together, our results suggest the following work-
ing hypothesis of presynaptic dystrophic neurite formation 
and plaque progression (Fig. S6). During early stages of 
amyloid deposition, a plaque nidus forms stochastically in 
the parenchyma and is too small to be significantly toxic 
to axons and terminals. Following further Aβ addition, the 
plaque grows large enough to come into close proximity to 
a nearby axon or terminal and causes neurotoxicity derived 
from high local concentrations of either soluble Aβ oligom-
ers or insoluble Aβ fibrils. An as yet undefined cascade is 
triggered that leads to local destabilization and/or depolym-
erization of microtubules in the axon; microtubules in more 
distant regions of the axon are unaffected. Microtubule-
dependent axonal transport is impaired locally in the region 
of the axon nearest the plaque in which microtubules are 
disrupted, although transport is normal in segments further 
away from the plaque. Vesicles proximal and distal to the 
plaque undergoing anterograde and retrograde transport, 
respectively, detach from the ends of disrupted microtu-
bules and begin to accumulate causing swelling and axonal 
dystrophy nearest the plaque. The accumulation of vesicles 
containing APP, BACE1, and γ-secretase leads to increased 
APP processing and Aβ generation in the dystrophic region 
of the axon and may accelerate growth and development 
of the nearby plaque. This in turn results in a feed-for-
ward mechanism of increased axonal dystrophy, BACE1 
and APP accumulation, and Aβ generation. Together with 
dysfunction associated with axonal swelling and impaired 
transport, this cascade is likely to exacerbate downstream 
neurodegeneration leading to cognitive deficits. Despite 
being likely of presynaptic origin, peri-plaque dystrophies 
lack a structural protein of active zones, bassoon, suggest-
ing that they are not functional in synaptic transmission. 
Importantly, this cascade would disrupt vesicular traffick-
ing from the soma to the terminal and vice versa. Protein 
turnover could be inhibited resulting in accumulation of 
certain proteins like BACE1, and loss of others according 
to the specific cellular mechanisms by which their transport 
and degradation are controlled. In future work, it will be 
important to determine the potential roles of other major 
players in dystrophic neurite generation, such as Reticulon 
3, which has been implicated in dystrophic neurite forma-
tion [19, 52, 53], or the recently discovered η-secretase 
processing of APP [73] (see Supplementary Text, Fig. S7), 
in the processes that we describe here.
Our data suggest that BACE1-positive peri-plaque dys-
trophic neurites are axonal or terminal in origin due to the 
presence of the predominantly axonal protein neurofilament 
NF-M [25, 74], synaptic vesicle protein synaptophysin 
(Fig. 6b) [25, 85, 86] and myelination (Fig. 4), and absence 
of the somatodendritic protein MAP2 (Fig. 6c) [25, 85, 
86]. Moreover, endogenous BACE1 is highly concentrated 
in vesicles of presynaptic terminals [25]. Consistent with 
our results, other APP transgenic mice have peri-plaque 
APP-positive dystrophies that stain for synaptophysin and 
the presynaptic vesicular glutamate transporter VGLUT1 
but lack MAP2, and also have dystrophies that are myeli-
nated and accumulate autophagic intermediates by EM 
[50]. VGLUT1 and other presynaptic markers includ-
ing growth-associated protein 43 (GAP43), glutamic acid 
Fig. 9  BACE1 accumulation in peri-plaque dystrophic neurites 
increases BACE1 cleavage of APP and generation of Aβ42. Sagittal 
brain sections of 5XFAD mice were co-immunostained with anti-
bodies recognizing BACE1 and cleaved APP fragment neoepitopes 
(sAPPβ, 3D6, Aβ42) validated in Fig. 8. a The BACE1-cleaved free 
C-terminal neoepitope of sAPPβ (ANJJ, green) showed robust co-
localization with elevated BACE1 (red) in peri-plaque dystrophic 
neurites. Note the intense sAPPβ immunoreactivity in dystrophies, 
while little if any sAPPβ signal is present in surrounding neuropil, 
demonstrating dramatically elevated BACE1 cleavage of APP in 
BACE1-positive dystrophic neurites near amyloid deposits. b Anti-
body 3D6 (green), which recognizes the free N-terminal neoepitope 
of BACE1-cleaved Aβ, also co-localized with elevated BACE1 (red) 
in dystrophic neurites, confirming increased BACE1 activity and 
Aβ generation in dystrophies. Antibody 3D6 also detects amyloid 
plaques, as expected (example marked with asterisk). c Like 3D6, 
an antibody recognizing the free C-terminal neoepitope generated 
after γ-secretase cleavage of Aβ42 (green) co-localized with ele-
vated BACE1 (red) in peri-plaque dystrophies, and detected amyloid 
deposits, as expected (asterisk). d Co-immunostaining also demon-
strated that both sAPPβ (green) and 3D6 (Aβ, red) neoepitopes co-
localized in peri-plaque dystrophies. e Co-immunostaining with anti-
bodies against BACE1 (red) and APP (Karen, green) also showed a 
high level of co-localization. Note that all cleaved APP fragment 
neoepitopes and BACE1 show a punctate immunostaining pattern 
in dystrophies, suggesting that they are localized to vesicles such 
as endosomes, while APP immunostaining appears more uniform, 
implying greater cell surface localization. Panels in the right column 
of each set are high-magnification images of the boxed regions in 
the frames of the left column. DAPI staining (blue) identified nuclei 
and autofluorescence of amyloid deposit cores (marked by asterisks). 
Scale bar sizes are indicated in bottom panels for images in each col-
umn
◂
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decarboxylase 67 (GAD67), and choline acetyltransferase 
(ChAT) have also been shown to co-localize with BACE1 
in dystrophic neurites, supporting their presynaptic/axonal 
origin [85]. Although lack of BACE1 and MAP2 co-locali-
zation does not guarantee that BACE1-positive dystrophies 
are not dendritic, the robust co-localization of BACE1 with 
five presynaptic markers strongly suggests presynaptic ori-
gin. The absence of synaptic active zone scaffold protein 
bassoon in BACE1-positive dystrophies (Fig. 6a) could be 
caused by loss of normal synaptic structure. The post-syn-
aptic density protein PSD95 is also reduced around plaques 
[29], supporting this hypothesis. Thus, the majority of evi-
dence suggests that BACE1-positive peri-plaque dystro-
phies are presynaptic in origin, although we cannot exclude 
the possibility that some BACE1-positive dystrophic neur-
ites are post-synaptic/dendritic in nature.
There has been much debate about whether plaques are 
a toxic agent in Alzheimer’s disease, or a mechanism for 
the brain to sequester amyloid in a less harmful form. Early 
reports indicated that plaque load did not correlate well 
with cognitive impairment [1, 59]. However, recent work 
has shown that cerebral amyloid deposition identified by 
amyloid-PET imaging in cognitively normal and mildly 
impaired individuals predicts conversion to AD [22]. Fur-
thermore, numerous studies have documented toxic effects 
such as mitochondrial loss [77], oxidative damage [78], 
synapse loss [29], and spine loss [75] in the immediate 
vicinity of plaques. In our study, we found that dystrophic 
neurites appear to be in contact with amyloid plaques at 
the ultrastructural level (Fig. 4), by immunofluorescence 
microscopy (Figs. 3, 5, 6, 9, S3, S4) and in live slices by 
multi-photon confocal microscopy (Fig. S5; Videos S1, 
S2), whereas areas of neuropil slightly further away are 
morphologically normal. Interestingly, a study using an 
antibody specific to oligomeric Aβ (NAB61) determined 
that a halo of oligomeric Aβ extends ~6.5 μm beyond the 
edge of the fibrillar Aβ core [29]. These results suggest 
that plaques are sources of soluble Aβ oligomers, widely 
thought to be the toxic species in AD, that are in dynamic 
equilibrium with insoluble Aβ deposits, thus creating high 
local concentrations of neurotoxic Aβ.
Previous studies have reported that soluble Aβ levels in 
the brain are in the picomolar range [33, 76]. However, this 
estimate is based on biochemical isolation of Aβ from post-
mortem brain lysates and thus is the average concentration 
of soluble Aβ in the brain, but it may not reflect the local 
soluble Aβ concentration near the plaque. To our knowl-
edge, absolute soluble Aβ concentrations in the immediate 
vicinity of the plaque have not been quantified. Although 
a halo of Aβ oligomers emanating from individual plaques 
has been demonstrated [29], the absolute quantification of 
soluble peri-plaque Aβ concentrations was not performed 
in this study. Thus, we suggest that local peri-plaque 
concentrations of soluble Aβ may be much higher than 
average Aβ concentrations in the brain. If so, high local 
soluble Aβ concentrations may cause microtubule disrup-
tion and neuritic swelling in the portion of the neurite that 
is very near the plaque, but parts of the neurite that are far-
ther away would be exposed to lower soluble Aβ concentra-
tions that may not induce neuritic dystrophy. Such a local-
ized effect on only the peri-plaque portion of the neurite 
may not induce cell death processes in the distant cell body, 
at least not initially. This scenario is consistent with both 
our in vitro and in vivo results.
Although it is challenging to measure Aβ oligomer con-
centrations in the halo surrounding the amyloid deposit, 
the local concentrations of Aβ may reach very high values 
approaching the plaque. We used relatively high concentra-
tions of Aβ42 oligomers (1–10 μM) in our primary neuron 
experiments to model the high local oligomeric Aβ42 con-
centration in the immediate vicinity of the amyloid deposit. 
It is unlikely that microtubule disruption (Figs. 1, 2) and 
axonal transport impairment (Fig. S2) in Aβ42-treated pri-
mary neurons were the result of cell death processes, since 
propidium iodide staining showed no increase in dead 
cells in the Aβ42-treated cultures (Fig. S1). Additionally, 
we previously showed that 5 days of treatment with 1 or 
2 μM Aβ42 oligomers caused no significant increase of 
activated caspase 3 in primary neurons [49]. Microtubule 
disruption may occur at concentrations lower than 1 μM 
Aβ42, although we have not tested this yet. However, a pre-
vious study has shown that 0.5 μM Aβ42 oligomers does 
not appear to disrupt microtubules in primary neurons [7], 
suggesting that 1 μM Aβ42 may be a threshold concentra-
tion for microtubule disruption. The relationship between 
our in vitro and in vivo results still requires further inves-
tigation, but even in aged 5XFAD mice with high levels 
of soluble Aβ42, we observe microtubule disruption and 
aberrant tubulin localization only in the immediate vicin-
ity of amyloid deposits, suggesting that high Aβ42 concen-
trations are necessary for these effects. When conditional 
expression of APP in transgenic mouse brain is reduced 
by over 90 % with doxycycline treatment, Aβ40 and Aβ42 
levels in interstitial fluid drop by about 70 %, suggesting 
that while plaques are fairly stable over time, they do con-
tribute to soluble Aβ in the brain [13]. The hypothesis has 
been advanced that the toxic species of Aβ is generated in 
plaques, as the Aβ bound there over time becomes modi-
fied, gaining neurotoxicity [83]. Alternatively, insoluble 
fibrillar Aβ in plaques could be directly neurotoxic, or indi-
rectly induce toxicity through secondary mechanisms such 
as neuroinflammation. Much future research remains to 
precisely define the exact neurotoxic species of Aβ in AD.
The cellular and molecular mechanisms leading to amy-
loid-induced microtubule disruption and axonal dystrophy 
are not yet clear. Recent studies investigating the effects 
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of Aβ42 oligomers on Tau mis-sorting indicate that the 
microtubule-severing enzyme spastin mediates microtubule 
breakdown in dendrites [82]; however, a role for this mech-
anism in axons is unclear. It is unlikely that Tau is directly 
involved in the generation of dystrophic neurites, as hAPP; 
Tau−/− mice have the same plaque area and same percent-
age of plaques with dystrophic neurites as hAPP; Tau+/+ 
mice despite having improved survival and cognitive func-
tion [47]. Importantly, the absence of Tau did not affect the 
generation of APP-positive dystrophies that, based upon 
our results, were also likely BACE1-positive (Fig. 9e). 
These results suggest that Tau has an important role in 
Aβ-related cognitive deficits, but Tau does not appear cen-
tral to the effects of amyloid deposits on dystrophic neu-
rite formation. It is more likely that depolymerization of 
microtubules affects Tau phosphorylation, mis-sorting, and 
aggregation.
Aβ42 oligomers have been proposed to mediate toxic-
ity through a number of extracellular receptors such as 
glutamate receptors, p75 neurotrophin receptors, nicotinic 
acetylcholine receptors, amylin receptors, the receptor for 
advanced glycation end products (RAGE), insulin and IGF 
receptors, and others (reviewed in [42]). Activation of these 
receptors leads to changes in LTP, modulation of various 
signaling cascades, including Jun kinase, p38, MAPKs 
and p53, as well as caspase activation (reviewed in [42]), 
some of which can cause apoptosis and cell death. Oligo-
meric Aβ42 leads to synaptic dysfunction that correlates 
with cognitive decline, perhaps mediated through effects 
on NMDA receptors [63]. One study showed that NMDA 
receptor antagonists and GSK3β inhibitors prevented Aβ 
oligomer-induced disruption of axonal trafficking, suggest-
ing that these pathways are involved [7].
The identity of BACE1-positive vesicles in peri-plaque 
dystrophic axons is not yet clear. Our previous EM analy-
sis indicates that the dystrophies are heterogeneous, some 
containing smaller, clear vesicles, possibly endosomes, 
and others containing larger, multi-lamellar, electron-dense 
vesicles that may be autophagic/lysosomal intermediates 
[25]. By immuno-EM, BACE1 is predominantly found 
in dystrophies with small, electron-translucent vesicles. 
Recent work indicates that large numbers of Lamp1-posi-
tive immature lysosomes accumulate around plaques, and 
that BACE1 co-localizes with Lamp1, suggesting BACE1 
accumulation in immature lysosomes [15]. Although we 
have observed Lamp1 [25] and cathepsin D (this study) 
accumulation in peri-plaque dystrophies, co-localization 
of these lysosomal proteins with BACE1 is limited, sug-
gesting that BACE1 trafficking to lysosomes is impaired. 
Additionally, our data showing elevated immature proteo-
lytically inactive pro-cathepsin D in 5XFAD brains sup-
port the hypothesis that lysosomal maturation is impaired, 
which could reduce the degradation of BACE1 and cause 
it to accumulate. Further studies are needed to better char-
acterize the heterogeneity of peri-plaque dystrophies, and 
determine its causes and consequences.
While we clearly observed Aβ42 in presynaptic dys-
trophic neurites around plaques, future investigation must 
determine whether these dystrophies are a significant source 
of Aβ42 for plaque growth. Local Aβ generation should be 
higher in plaque-rich than in plaque-poor brain regions, and 
in older APP transgenic mice with elevated BACE1, com-
pared to young animals. If so, these data could indicate that 
stabilization of microtubules might be beneficial in slowing 
pathology and plaque growth, and perhaps preserve neu-
ronal and cognitive function for the treatment of AD.
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